Literature DB >> 25717269

Hepatitis B reactivation and timing for prophylaxis.

Nazan Tuna1, Oguz Karabay1.   

Abstract

It is known that immunotherapy and cancer chemotherapy may cause hepatitis B virus (HBV) reactivation in hepatitis B surface antigen carriers and inactive chronic hepatitis B patients. Guidelines recommend antiviral prophylaxis regardless of HBV DNA levels to prevent reactivation. We read from the article written by Liu et al that Lamivudine was given inadequate time for antiviral prophylaxis.

Entities:  

Keywords:  Antiviral prophylaxis; Hepatitis B; Hepatitis B reactivation; Immunotherapy; Inadequate time; Lamivudine

Mesh:

Substances:

Year:  2015        PMID: 25717269      PMCID: PMC4326171          DOI: 10.3748/wjg.v21.i7.2263

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  3 in total

1.  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

Authors: 
Journal:  J Hepatol       Date:  2012-03-20       Impact factor: 25.083

Review 2.  Current trends in management of hepatitis B virus reactivation in the biologic therapy era.

Authors:  Claudio M Mastroianni; Miriam Lichtner; Rita Citton; Cosmo Del Borgo; Angela Rago; Helene Martini; Giuseppe Cimino; Vincenzo Vullo
Journal:  World J Gastroenterol       Date:  2011-09-14       Impact factor: 5.742

3.  Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.

Authors:  Wei-Ping Liu; Wen Zheng; Yu-Qin Song; Ling-Yan Ping; Gui-Qiang Wang; Jun Zhu
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

  3 in total
  2 in total

1.  Use of entecavir in hepatitis B virus reactivation of a patient with non-Hodgkin's lymphoma.

Authors:  Hasan Tahsin Gozdas; Erkan Arpaci
Journal:  World J Gastroenterol       Date:  2015-09-21       Impact factor: 5.742

Review 2.  Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations.

Authors:  Fernando Bessone; Melisa Dirchwolf
Journal:  World J Hepatol       Date:  2016-03-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.